Pricing Log in Create free account

Can-Fite Biopharma Ltd (CANF) vs Imunon, Inc. (IMNN)

Can-Fite Biopharma Ltd and Imunon, Inc. are both Biotechnology companies. Can-Fite Biopharma Ltd and Imunon, Inc. are of similar size ($5.1M and $4.9M). Imunon, Inc. grew revenue faster over the last twelve months: 0.00% against −3.36%. Imunon, Inc. has the higher net margin (0.00% vs −1,148.6%) and the lower return on invested capital (−324.4% vs 0.00%). Across the 15 metrics below, Can-Fite Biopharma Ltd leads on 8 and Imunon, Inc. on 7.

Valuation

Metric CANF IMNN Biotechnology median
P/E n/m n/m 10.60
P/S 0.41 8.90 9.40
P/B 0.07 2.30 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.58 n/m 0.66
EV/Sales (8.67) 6.23 9.02
Earnings yield (802.80%) (450.59%) (32.88%)
Free cash flow yield (6,017.34%) (341.72%) (23.13%)

Profitability

Metric CANF IMNN Biotechnology median
Gross margin 0.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin (1,148.62%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (641.02%) (51.96%)
Return on assets 0.00% (123.93%) (46.06%)
Return on invested capital 0.00% (324.37%) 0.00%

Growth

Metric CANF IMNN Biotechnology median
Revenue growth (TTM) (3.36%) 0.00% 6.76%
EPS growth (last fiscal year) 45.23% 59.68% 29.88%
Revenue growth, 5-year CAGR (11.90%) 0.00% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CANF IMNN Biotechnology median
Debt to equity 0.00 1.32 0.00
Current ratio 3.60 1.82 4.97
Net debt to EBITDA 0.86 0.63 1.01

Dividend

Metric CANF IMNN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CANF IMNN Biotechnology median
Market cap 4.86m 5.05m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack